Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis
Open Access
- 1 September 2023
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 202 (1) , 11-22
Abstract
Purpose: Breast cancer and its treatments may increase the risk of type 2 diabetes (T2D). We conducted a systematic review and meta-analysis to investigate the association between breast cancer and the incidence of T2D overall, and according to breast cancer treatments. Methods: We searched PubMed, Embase and references of relevant papers for studies on breast cancer, breast cancer treatment, and subsequent T2D risk. Using random-effects models, we calculated effect estimates and associated 95% confidence intervals of the association between breast cancer, adjuvant breast cancer treatments (i.e., endocrine therapy (tamoxifen, aromatase inhibitors, and combined) and chemotherapy), and subsequent T2D. We used funnel plots to assess publication bias. Results: Among 15 eligible studies, 10 reported on T2D risk after breast cancer, chemotherapy, or endocrine therapy; five studies investigated more than one association. Compared with patients without breast cancer, those with breast cancer and those who received any endocrine therapy had elevated risk of incident T2D (EE = 1.23, 95% CI = 1.13–1.33 and EE = 1.23, 95% CI = 1.16–1.32, respectively). Among breast cancer patients only, the risk of T2D was higher for those who received tamoxifen compared with those who did not receive tamoxifen (EE = 1.28, 95% CI = 1.18–1.38). Due to few studies, analyses investigating T2D risk after treatment with aromatase inhibitors or chemotherapy were inconclusive. Conclusion: Our findings suggest an elevated risk of T2D in breast cancer survivors, particularly after tamoxifen therapy. Further research is needed to determine the impact of aromatase inhibitors, and chemotherapy on the incidence of T2D after breast cancer.Keywords
Funding Information
- Novo Nordisk Fonden (NNF20OC0065928)
- Riisfort Fonden
- Kræftens Bekæmpelse (R328-A19070)
This publication has 34 references indexed in Scilit:
- Incidences of diabetes and prediabetes among female adult breast cancer patients after systemic treatmentMedical Oncology, 2013
- Association between tamoxifen treatment and diabetesCancer, 2011
- Diabetes and breast cancer among women with BRCA1 and BRCA2 mutationsCancer, 2010
- Weight gain in breast cancer survivors: prevalence, pattern and health consequencesObesity Reviews, 2010
- The pancreatic β-cell as a target of estrogens and xenoestrogens: Implications for blood glucose homeostasis and diabetesMolecular and Cellular Endocrinology, 2009
- Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast CancerCancer Research, 2008
- Estrogens protect pancreatic β-cells from apoptosis and prevent insulin-deficient diabetes mellitus in miceProceedings of the National Academy of Sciences, 2006
- Association between diabetes mellitus and adverse characteristics of breast cancer at presentationEuropean Journal of Cancer, 2006
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004Journal of Clinical Oncology, 2005
- A comparison of the logistic risk function and the proportional hazards model in prospective epidemiologic studiesJournal of Chronic Diseases, 1983